Replimune Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
REPL Nasdaq 2836 www.replimune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Replimune Group, Inc.

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 6th, 2025 2:01 pm
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 1st, 2025 8:00 am
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - May 29th, 2025 6:00 am
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - May 23rd, 2025 1:03 am
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - May 22nd, 2025 5:00 am
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 16th, 2025 6:00 am
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - Feb 12th, 2025 6:00 am
Replimune price target raised to $21 from $17 at H.C. Wainwright - Jan 23rd, 2025 5:06 am
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Jan 22nd, 2025 9:37 am
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Jan 21st, 2025 11:01 am
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - Jan 21st, 2025 6:00 am
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials - Jan 8th, 2025 6:00 am
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 23rd, 2024 6:00 am
Replimune Announces Pricing of Upsized Public Offering - Nov 25th, 2024 9:55 pm
Replimune Announces Proposed Public Offering - Nov 25th, 2024 5:09 am
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results - Nov 22nd, 2024 2:00 pm
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug - Nov 22nd, 2024 9:23 am
Replimune's stock surges 19% after-hours on FDA BLA submission - Nov 22nd, 2024 3:48 am
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - Nov 21st, 2024 2:05 pm
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2024 6:00 am